Brentuximab for adults with Hodgkin’s lymphoma after stem cell plans
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how well brentuximab vedotin works for adults with Hodgkin’s lymphoma who have either already had, or are being considered for, stem cell transplant. It may help people who are receiving a specific treatment plan to control the lymphoma after transplant planning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have either had an autologous stem cell transplant (ASCT) or are being considered for it
- You are currently in—or are a candidate for—the specific treatment program (BV HL NDP) being used with Adcetris
- You cannot be taking part in another clinical trial that involves a treatment decision or change
- Your study doctor must agree that it’s safe and appropriate for you to join
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a treatment plan for adults with Hodgkin lymphoma that has returned or did not respond to ABVD chemotherapy. It may help people with a higher-risk pattern of disease, as long as their organ function and overall health meet study limits.
This trial is a survey study that looks at how brentuximab vedotin is used in children with Hodgkin lymphoma. It focuses on people whose tumor is CD30-positive and who have not had prior treatment, to see how the drug fits with a standard chemotherapy plan (AVD).
This trial tests a combination of the targeted drug brentuximab vedotin with standard chemotherapy (doxorubicin, vinblastine, and dacarbazine) for adults with Stage 3 or 4 Hodgkin lymphoma who have not had previous treatment. It aims to see if this combination works well and is safe.
This Phase 3 trial studies whether adding brentuximab vedotin to standard chemotherapy improves outcomes for people with newly diagnosed early-stage classical Hodgkin lymphoma. It may help reduce the chance the cancer returns or improves how well treatment works.
This trial tests a combination of two drugs (brentuximab vedotin, AVD chemotherapy) for people with newly diagnosed, bulky Hodgkin lymphoma that hasn't spread far. It aims to see if this treatment works well for larger tumors.
This Phase 2 trial tests whether pembrolizumab plus brentuximab works better than standard chemotherapy followed by an autologous stem cell transplant for people whose classic Hodgkin lymphoma has come back or did not respond. It may help by improving cancer control before and around stem cell transplant and by comparing outcomes between the two treatment approaches.
Hear when a new Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.